leisure time -WSS

leisure time

author：hotspot 2025-10-02 23:48:32 - browse：961

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Cybersecurity threat forces Lurie Children's to take systems offline

explore

WSS

Time to name cancers by genetics, not organ of origin, expert says

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Free Covid tests will again be offered to all U.S. households

Novo Nordisk to expand supply of Wegovy for U.S. patients

Medicare to pay more for cardiac rehab in hospital outpatient clinics

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

entertainment

leisure time

The next ALS data readout — overdue but important

hotspot

How one medical school became remarkably diverse

Why the drug industry's warnings on the IRA's impact fall short

Dobbs anniversary: the lost opportunity of abortion as health care

Neurocrine congenital adrenal hyperplasia trial succeeds

Wildfire smoke exposes gaps in outdoor worker protections

Fed up with FDA, ALS advocates consider a take

Medical leaders decry Supreme Court decision on affirmative action

Juul spent big to court Black leaders to promote its e

How to save PrEP access — and even expand it

Some dementia cases could be undiagnosed liver disease

focus

'A game

David Liu startup to focus on CRISPR delivery

Biden administration opens offers in Medicare drug price negotiations

Why the drug industry's warnings on the IRA's impact fall short

What we need to know about Arena Bioworks

Medicare to pay more for cardiac rehab in hospital outpatient clinics

explore

explore

leisure time

knowledge